Search 

20/20 GeneSystems, headquartered in Rockville, Maryland (outside of Washington, D.C.), is a revenue stage diagnostics company that uses machine learning algorithms to greatly improve the accuracy of laboratory tests for the early detection of cancer and other diseases.  In the most recent calendar year our revenues grew to over $2 million aided by several COVID-19 tests that we are successfully commercializing. 

 

Our multi-cancer early detection blood test (www.OneTest.Ai) measures tumor antigens and uses a machine learning algorithm powered by outcome data from over 230,000 individuals tested in real-world screening settings.  OneTest is a highly accessible and affordable pre-test that can be followed up with more expensive and specific circulating tumor DNA tests such as those being developed by Grail and Thrive Earlier Detection.  (Those companies were recently acquired for $8 billion and $2 billion respectively.)      

 

20/20’s institutional investors include Ping An, one of the largest digital health and insurance companies in China, and several well-regarded American funds.   We are working to an initial public offering in 2021 and are now lining up IPO “crossover” investors.

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.

Abbott Medicine Division

ACON Pharmaceuticals Inc. (ACON Pharma) is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system and technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.

We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.

MNC pharmaceuticals company

Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, and fintech spaces. a16z has nearly $16.5B in assets under management across multiple funds, including the $1.4B Bio funds, the $865M Crypto funds, and the Cultural Leadership Fund.

a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and who have domain expertise ranging from biology to crypto to distributed systems to security to marketplaces to financial services.

We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, and others in the technology ecosystem. We have built a network of experts including technical and executive talent; top media and marketing resources; Fortune 500/Global 2000 companies; as well as other technology decision makers, influencers, and key opinion leaders. a16z uses this network as part of our commitment to help our portfolio companies grow their business, so our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company building.

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.

Focused in genitourinary（GU）/women health field with 2 global assets for bladder cancer and pre-cervical cancer treatment in phase 3 stages，looking for in/out-licensing partnership in GU/women health area